Specific RNA-guided cell depletion
Akribion Therapeutics is developing a unique, RNA-guided, nuclease enzyme-based technology for programmable cell depletion using its G-dase® E payload.
Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), we are developing and exploring applications in precision oncology and beyond.
Specific and precise
Up to single nucleotide specificity in differentiation of unwanted vs. healthy cells
Flexible target selection
To choose a new target, only a short gRNA needs to be exchanged
Broad application potential
Potentially gamechanging therapeutic applications in many disease areas
Want to contact us?
Feel free to reach out!